{
    "pmcid": "10858559",
    "qa_pairs": {
        "What advantage do nanobodies have over conventional antibodies according to the study?": [
            "They can access hidden epitopes and penetrate tissues more effectively",
            "They have a longer half-life in the bloodstream",
            "They are more likely to cross-react with human proteins",
            "They are larger and more stable than conventional antibodies"
        ],
        "What is a key consideration for the expression and purification of nanobodies as highlighted in the study?": [
            "Using a prokaryotic system for cost-effective and scalable production",
            "Utilizing a eukaryotic system for higher yield",
            "Employing a viral vector for expression",
            "Relying on chemical synthesis for purification"
        ],
        "What is the primary target of the nanobodies developed in the study?": [
            "SRMV fusion (F) and hemagglutinin (H) proteins",
            "SARS-CoV-2 spike protein",
            "Human ACE2 receptor",
            "SRMV nucleoprotein"
        ],
        "What is the significance of the nanobody NbSRMV-1-21 mentioned in the study?": [
            "It demonstrated neutralizing activity against SRMV",
            "It showed cross-reactivity with other viruses",
            "It was unable to bind to SRMV proteins",
            "It failed to express in a prokaryotic system"
        ],
        "Which technology was used to construct the VHH library in the study?": [
            "Phage display technology",
            "CRISPR-Cas9 gene editing",
            "Yeast two-hybrid system",
            "RNA interference"
        ]
    }
}